Worldwide Behavioural & Mental Health Software Industry to 2026 – Growing Awareness of Subscription Models Presents Opportunities – Yahoo Finance

Share Article

Argus will discuss their 2022 forecasts on Tuesday, 12/14 at 2PM ET as the pandemic continues to challenge the markets.
DUBLIN, Dec. 8, 2021 /PRNewswire/ — The "Global Behavioural & Mental Health Software Market (2021-2026) by Component, Service, Function, Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis" report has been added to's offering.
The Global Behavioural & Mental Health Software Market is estimated to be USD 2.95 Bn in 2021 and is expected to reach USD 4.41 Bn by 2026, growing at a CAGR of 8.36%.

Mental health software facilitates interactive health care sources to choose the right treatment for a person enduring trauma, depression, liquor, and anxiety. The patient's health documents or specifics and therapeutic history background are used to prepare or build the proposal. Being indebted to the escalating prevalence of stress, anxiety, and depression, the patients gradually seek care. Therefore, healthcare workers use computerized technologies to monitor behavioral/mental safety. These factors are fuelling the studied market growth.

According to WHO data from 2020, depression is the most widespread medical disease and one of the foremost causes of disability, affecting around 264 million people globally. Corresponding to reports, the system allows consumers to arrange meetings online and give medical bills using mobile gadgets such as smartphones and laptops. This will create huge market opportunities in both emerging and developed countries.

However, the factors such as data privacy issues and limited IT professionals in healthcare organizations will hinder the market growth.

Company Profiles
Some of the companies covered in this report are Core Solutions, Ginger, Mind Linc, EMIS Health, Peer Therapeutics, Lark Health etc.

Competitive Quadrant
The report includes Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.

Why buy this report?
The report offers a comprehensive evaluation of the Global Behavioural & Mental Health Software Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.
The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.
The report includes an in-depth market analysis using Porter's 5 forces model and the Ansoff Matrix. In addition, the impact of Covid-19 on the market is also featured in the report.
The report also includes the regulatory scenario in the industry, which will help you make a well-informed decision. The report discusses major regulatory bodies and major rules and regulations imposed on this sector across various geographies.
The report also contains the competitive analysis using Positioning Quadrants, the analyst's Proprietary competitive positioning tool.
Report Highlights:
A complete analysis of the market, including parent industry
Important market dynamics and trends
Market segmentation
Historical, current, and projected size of the market based on value and volume
Market shares and strategies of key players
Recommendations to companies for strengthening their foothold in the market
Key Topics Covered:

1 Report Description

2 Research Methodology

3 Executive Summary

4 Market Influencers
4.1 Drivers
4.1.1 Increasing Adoption of Behaviour Health Systems
4.1.2 Growing m-Health and Telehealth Services
4.1.3 Rising Government Funding to Support Progressive Adoption
4.2 Restraints
4.2.1 Data Privacy and Technical Issues
4.2.2 Limited IT Know-How in Healthcare Organizations
4.3 Opportunities
4.3.1 Market Potential in Emerging Markets
4.3.2 Growing Awareness of Subscription Models
4.4 Challenges
4.4.1 Financial Limitations in Emerging Countries
4.5 Trends

5 Market Analysis
5.1 Regulatory Scenario
5.2 Porter's Five Forces Analysis
5.3 Impact of COVID-19
5.4 Ansoff Matrix Analysis

6 Global Behavioural & Mental Health Software Market, By Component
6.1 Introduction
6.2 Software
6.2.1 Integrated Software
6.2.2 Standalone Software
6.3 Support Services

7 Global Behavioural & Mental Health Software Market, By Service
7.1 Introduction
7.2 Private Practices
7.3 Community Clinics
7.4 Hospitals

8 Global Behavioural & Mental Health Software Market, By Function
8.1 Introduction
8.2 Clinical Functionality
8.2.1 Electronic Health Records (EHR)
8.2.2 E-Prescribing
8.2.3 Clinical Decision Support (CDS)
8.2.4 Care Plans/Health Management
8.2.5 Telehealth
8.3 Administrative Functionality
8.3.1 Patient/Client Scheduling
8.3.2 Case Management
8.3.3 Business Intelligence (BI)
8.3.4 Document/Image Management
8.3.5 Workforce Management
8.4 Financial Functionality
8.4.1 Managed Care
8.4.2 Revenue Cycle Management
8.4.3 Accounts Payable/General Ledger
8.4.4 Payroll

9 Global Behavioural & Mental Health Software Market, By Geography

10 Competitive Landscape
10.1 IGR Competitive Quadrant
10.2 Market Share Analysis
10.3 Strategic Initiatives
10.3.1 M&A and Investments
10.3.2 Partnerships and Collaborations
10.3.3 Product Developments and Improvements

11 Company Profiles
11.1 Accumedic
11.2 Advanced Data Systems
11.3 AdvancedMD
11.4 Allscripts
11.5 Big Health
11.6 Blackthorn Therapeutics
11.7 Cerner
11.8 Compulink
11.9 Core Solutions
11.10 Credible Behavioural Health
11.11 Cure MD
11.12 EMIS Health
11.13 eNeura
11.14 Epic Systems Corporations
11.15 Ginger
11.16 Happify Health
11.17 Holmusk
11.18 Kareo
11.19 Karuna Pharmaceuticals
11.20 Lark Health
11.21 Lyra Health
11.22 Meditab Software
11.23 Mediware
11.24 MindLinc
11.25 Netsmart
11.26 NextGen Healthcare
11.27 Pear Therapeutics
11.28 Qualifacts
11.29 The Echo Group
11.30 Valant
11.31 Welligent

12 Appendix
For more information about this report visit
Media Contact:
Research and Markets
Laura Wood, Senior Manager

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
View original content:–mental-health-software-industry-to-2026—growing-awareness-of-subscription-models-presents-opportunities-301440517.html
SOURCE Research and Markets
Yahoo Finance Live anchors Zack Guzman and Akiko Fujita look at EV developer Lucid Group's plunge amid sell-offs of convertible senior notes and an SEC subpoena over its SPAC deal.
Many growth stocks fell on Thursday, as investors rotated out of premium-priced companies. By the close of trading, shares of Nvidia (NASDAQ: NVDA), Advanced Micro Devices (NASDAQ: AMD), and Unity Software (NYSE: U) were down 4%, 5%, and 9%, respectively. A tight labor market could lead to higher wages, which could, in turn, stoke inflation.
The Wall Street giant sees plenty of stocks worth buying at their current prices.
Bill Gates looks for income, too. This is how he gets it.
With electric vehicle (EV) maker Tesla valued at more than $1 trillion and Rivian, which has so far produced fewer than 200 vehicles, valued at more than $100 billion, value-focused investors may find staying away from the EV stock space to be the best course of action right now. Trying to understand the valuations of EV stocks has become challenging lately. Not all EV stocks are getting valued the same way.
The new market rally is getting its first test as Tesla led a growth sell-off. A key inflation report is on tap.
The biotech, which concentrates on developing treatments for cancer, saw its share price dive by nearly 18% on the day. In August, the company's Biologics License Application (BLA) was rejected by the Food and Drug Administration (FDA). In its press release published just after the meeting, which Sesen Bio characterized as "productive," the company wrote that it now "believes it has greater clarity regarding the requirements for resubmission of the BLA and the trial design."
Shares of fintech giant Square (NYSE: SQ), soon to be known as Block, fell as much as 5.1% on Thursday as many growth stocks lost momentum. The biggest news of the day was that U.S. unemployment claims were just 184,000 last week, the lowest since 1969. A strong labor market is good for the economy, but it could also mean things like higher inflation and the Federal Reserve trying to push interest rates higher.
The fight against the coronavirus is an ongoing concern and is being tackled on many fronts. Arbutus Biopharma (ABUS) is another company in the hunt for solutions, and on Tuesday, the biotech announced it had achieved the first milestone based on its agreement with X-Chem and Proteros biostructures on the road to advancing an oral pan-coronavirus treatment. The company disclosed that it has identified a number of potent and selective small molecules which inhibit the SARS-CoV-2 nsp5 main proteas
The connected fitness company can't get growth investors to agree they should come along for the ride.
Broadcom Inc. shares rallied in the extended session Thursday after the chip and software company not only topped Wall Street estimates for the quarter but announced an aggressive program to return cash to investors.
Membership retailer Costco is set to report fiscal first-quarter earnings after easing from a big advance.
In this article, we discuss the 10 best stocks to buy now according to quant billionaire Jim Simons’ Fund. If you want to skip our detailed analysis of these stocks, go directly to the 5 Best Stocks to Buy Now According to Quant Billionaire Jim Simons’ Fund. Jim Simons, the chief of New York-based Renaissance […]
The Dow Jones inched higher. Tesla stock fell as Lucid Motors cratered. The Donald Trump SPAC fell hard after recent outperformance.
Yahoo Finance's Dan Howley explains what’s next for the tech behemoth as it eyes virtual reality, the metaverse, and an Apple car.
Shares of Kinross Gold (NYSE: KGC) slumped on Thursday after the miner announced a $1.4 billion deal to acquire Great Bear Resources. In a press release sent out on Wednesday, Kinross Gold announced its intent to acquire Great Bear Resources for $1.4 billion in stock and cash at a proposed price of 29 Canadian dollars per share. The target company owns a mining complex in Ontario, Canada, and it looks like Kinross Gold management thinks it could be a top-tier deposit area.
General Motors is locking up another portion of its electric-vehicle supply chain. That's good news for GM investors, and even better news for stock in the partner firm.
Lululemon Athletica releases its Q3 earnings, beating street estimates on both revenue and earnings per share.  
(Bloomberg) — Intel Corp. is railing against a proposed import ban on a key chipmaking ingredient, saying the move would worsen an already-perilous shortage of semiconductors. Most Read from BloombergAnatomy of a Bad RoadThe 15 Best Beers We Drank This YearThe World’s Relentless Demand for Chips Turns Deadly in MalaysiaSand and Soldiers Mix as Troops Move In to Protect Cancun TouristsFormer Oil Trader Is Now Betting on Lumber for SkyscrapersThe company is trying to dissuade the U.S. Internation
(Bloomberg) — Oracle Corp. reported better-than-expected quarterly revenue, buoyed by strong cloud sales and increased corporate demand for information technology. Shares rose about 10% in extended trading.Most Read from BloombergAnatomy of a Bad RoadThe 15 Best Beers We Drank This YearThe World’s Relentless Demand for Chips Turns Deadly in MalaysiaSand and Soldiers Mix as Troops Move In to Protect Cancun TouristsFormer Oil Trader Is Now Betting on Lumber for SkyscrapersSales increased 5.7% to


You might also like

Surviving 2nd wave of corona

Surviving The 2nd Wave of Corona

‘This too shall pass away’ this famous Persian adage seems to be defeating us again and again in the case of COVID-19. Despite every effort